Cargando…

2035. Clinical and Economic Outcomes in Patients with Complicated Urinary Tract Infection (cUTI) and Complicated Intra-Abdominal Infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) Resistant to Antibiotics

BACKGROUND: Delays in appropriate therapy of infections affect clinical outcomes. The aim of this study was to compare the clinical and economic outcomes of patients with cUTI and cIAI due to cephalosporin- and carbapenem-resistant GNOs to similar infections caused by nonresistant GNOs. METHODS: A r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hercilla, Luis, Perez, Giancarlo, Illescas, Ricardo, Hidalgo, Jose, Ramirez, Eresvita, Moreno, Vanesa, Galdos-Cardenas, Gerson, Gutierrez-Rodriguez, Raul, Rodriguez, Lourdes, Carlos Orengo, Juan, Monsanto, Homero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809546/
http://dx.doi.org/10.1093/ofid/ofz360.1715
_version_ 1783462015031836672
author Hercilla, Luis
Perez, Giancarlo
Illescas, Ricardo
Hidalgo, Jose
Ramirez, Eresvita
Moreno, Vanesa
Galdos-Cardenas, Gerson
Gutierrez-Rodriguez, Raul
Rodriguez, Lourdes
Carlos Orengo, Juan
Monsanto, Homero
author_facet Hercilla, Luis
Perez, Giancarlo
Illescas, Ricardo
Hidalgo, Jose
Ramirez, Eresvita
Moreno, Vanesa
Galdos-Cardenas, Gerson
Gutierrez-Rodriguez, Raul
Rodriguez, Lourdes
Carlos Orengo, Juan
Monsanto, Homero
author_sort Hercilla, Luis
collection PubMed
description BACKGROUND: Delays in appropriate therapy of infections affect clinical outcomes. The aim of this study was to compare the clinical and economic outcomes of patients with cUTI and cIAI due to cephalosporin- and carbapenem-resistant GNOs to similar infections caused by nonresistant GNOs. METHODS: A retrospective cohort study of patients admitted to two tertiary care hospitals in Lima-Callao, Peru between January and December 2017. Patients with resistant strains were compared with those with nonresistant strains for the failure of initial antibiotic regimen (defined as worsened clinical status, change of initial antibiotic treatment, or in-hospital mortality), median length of stay (LOS), hospitalization ward cost and total hospitalization cost. RESULTS: A sample of 500 consecutive culture-positive patients were included: 429 (86%) with cUTI and 71 (14%) with cIAI (table). CONCLUSION: cUTI caused by GNOs resistant to cephalosporins or carbapenems are associated with an incremental clinical and economic burden. The proportion of inappropriate therapy in patients with resistant infections is high. The cost of care for carbapenem-resistant cUTI was highest. The appropriate initial antibiotic choice may minimize the impact of GNO resistance on outcomes of patients with cIAI and cUTI. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809546
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68095462019-10-28 2035. Clinical and Economic Outcomes in Patients with Complicated Urinary Tract Infection (cUTI) and Complicated Intra-Abdominal Infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) Resistant to Antibiotics Hercilla, Luis Perez, Giancarlo Illescas, Ricardo Hidalgo, Jose Ramirez, Eresvita Moreno, Vanesa Galdos-Cardenas, Gerson Gutierrez-Rodriguez, Raul Rodriguez, Lourdes Carlos Orengo, Juan Monsanto, Homero Open Forum Infect Dis Abstracts BACKGROUND: Delays in appropriate therapy of infections affect clinical outcomes. The aim of this study was to compare the clinical and economic outcomes of patients with cUTI and cIAI due to cephalosporin- and carbapenem-resistant GNOs to similar infections caused by nonresistant GNOs. METHODS: A retrospective cohort study of patients admitted to two tertiary care hospitals in Lima-Callao, Peru between January and December 2017. Patients with resistant strains were compared with those with nonresistant strains for the failure of initial antibiotic regimen (defined as worsened clinical status, change of initial antibiotic treatment, or in-hospital mortality), median length of stay (LOS), hospitalization ward cost and total hospitalization cost. RESULTS: A sample of 500 consecutive culture-positive patients were included: 429 (86%) with cUTI and 71 (14%) with cIAI (table). CONCLUSION: cUTI caused by GNOs resistant to cephalosporins or carbapenems are associated with an incremental clinical and economic burden. The proportion of inappropriate therapy in patients with resistant infections is high. The cost of care for carbapenem-resistant cUTI was highest. The appropriate initial antibiotic choice may minimize the impact of GNO resistance on outcomes of patients with cIAI and cUTI. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809546/ http://dx.doi.org/10.1093/ofid/ofz360.1715 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Hercilla, Luis
Perez, Giancarlo
Illescas, Ricardo
Hidalgo, Jose
Ramirez, Eresvita
Moreno, Vanesa
Galdos-Cardenas, Gerson
Gutierrez-Rodriguez, Raul
Rodriguez, Lourdes
Carlos Orengo, Juan
Monsanto, Homero
2035. Clinical and Economic Outcomes in Patients with Complicated Urinary Tract Infection (cUTI) and Complicated Intra-Abdominal Infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) Resistant to Antibiotics
title 2035. Clinical and Economic Outcomes in Patients with Complicated Urinary Tract Infection (cUTI) and Complicated Intra-Abdominal Infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) Resistant to Antibiotics
title_full 2035. Clinical and Economic Outcomes in Patients with Complicated Urinary Tract Infection (cUTI) and Complicated Intra-Abdominal Infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) Resistant to Antibiotics
title_fullStr 2035. Clinical and Economic Outcomes in Patients with Complicated Urinary Tract Infection (cUTI) and Complicated Intra-Abdominal Infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) Resistant to Antibiotics
title_full_unstemmed 2035. Clinical and Economic Outcomes in Patients with Complicated Urinary Tract Infection (cUTI) and Complicated Intra-Abdominal Infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) Resistant to Antibiotics
title_short 2035. Clinical and Economic Outcomes in Patients with Complicated Urinary Tract Infection (cUTI) and Complicated Intra-Abdominal Infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) Resistant to Antibiotics
title_sort 2035. clinical and economic outcomes in patients with complicated urinary tract infection (cuti) and complicated intra-abdominal infection (ciai) in perú: impact of gram-negative organisms (gno) resistant to antibiotics
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809546/
http://dx.doi.org/10.1093/ofid/ofz360.1715
work_keys_str_mv AT hercillaluis 2035clinicalandeconomicoutcomesinpatientswithcomplicatedurinarytractinfectioncutiandcomplicatedintraabdominalinfectionciaiinperuimpactofgramnegativeorganismsgnoresistanttoantibiotics
AT perezgiancarlo 2035clinicalandeconomicoutcomesinpatientswithcomplicatedurinarytractinfectioncutiandcomplicatedintraabdominalinfectionciaiinperuimpactofgramnegativeorganismsgnoresistanttoantibiotics
AT illescasricardo 2035clinicalandeconomicoutcomesinpatientswithcomplicatedurinarytractinfectioncutiandcomplicatedintraabdominalinfectionciaiinperuimpactofgramnegativeorganismsgnoresistanttoantibiotics
AT hidalgojose 2035clinicalandeconomicoutcomesinpatientswithcomplicatedurinarytractinfectioncutiandcomplicatedintraabdominalinfectionciaiinperuimpactofgramnegativeorganismsgnoresistanttoantibiotics
AT ramirezeresvita 2035clinicalandeconomicoutcomesinpatientswithcomplicatedurinarytractinfectioncutiandcomplicatedintraabdominalinfectionciaiinperuimpactofgramnegativeorganismsgnoresistanttoantibiotics
AT morenovanesa 2035clinicalandeconomicoutcomesinpatientswithcomplicatedurinarytractinfectioncutiandcomplicatedintraabdominalinfectionciaiinperuimpactofgramnegativeorganismsgnoresistanttoantibiotics
AT galdoscardenasgerson 2035clinicalandeconomicoutcomesinpatientswithcomplicatedurinarytractinfectioncutiandcomplicatedintraabdominalinfectionciaiinperuimpactofgramnegativeorganismsgnoresistanttoantibiotics
AT gutierrezrodriguezraul 2035clinicalandeconomicoutcomesinpatientswithcomplicatedurinarytractinfectioncutiandcomplicatedintraabdominalinfectionciaiinperuimpactofgramnegativeorganismsgnoresistanttoantibiotics
AT rodriguezlourdes 2035clinicalandeconomicoutcomesinpatientswithcomplicatedurinarytractinfectioncutiandcomplicatedintraabdominalinfectionciaiinperuimpactofgramnegativeorganismsgnoresistanttoantibiotics
AT carlosorengojuan 2035clinicalandeconomicoutcomesinpatientswithcomplicatedurinarytractinfectioncutiandcomplicatedintraabdominalinfectionciaiinperuimpactofgramnegativeorganismsgnoresistanttoantibiotics
AT monsantohomero 2035clinicalandeconomicoutcomesinpatientswithcomplicatedurinarytractinfectioncutiandcomplicatedintraabdominalinfectionciaiinperuimpactofgramnegativeorganismsgnoresistanttoantibiotics